Theravance Biopharma, Inc. Increase (Decrease) in Accrued Liabilities
Theravance Biopharma, Inc. (TBPH) reported Increase (Decrease) in Accrued Liabilities of -$183.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-11
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $4.68M, a 46.74% increase year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$4.87M.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$1.27M, a 142.63% decline year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $3.61M, a 391.95% increase year-over-year.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was $4.01M, a 173.09% increase from fiscal 2024.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $1.47M.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was -$7.09M.
- Theravance Biopharma, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was -$14.09M.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month | Increase (Decrease) in Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$183.00K 10-Q · filed 2026-08-11 | -$1.46M derived: sum of 3 quarters · filed 2026-08-11 | $2.15M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2026-03-31 | -$4.87M 10-Q · filed 2026-05-07 | -$6.14M derived: sum of 2 quarters · filed 2026-05-07 | -$2.54M derived: sum of 3 quarters · filed 2026-05-07 | $656.00K derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-12-31 | -$1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $2.33M derived: sum of 2 quarters · filed 2026-03-23 | $5.52M derived: sum of 3 quarters · filed 2026-08-11 | $4.01M 10-K · filed 2026-03-23 | ||
| 2025-09-30 | $3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $6.80M derived: sum of 2 quarters · filed 2026-08-11 | $5.28M 10-Q · filed 2025-11-12 | $8.28M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-06-30 | $3.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $1.68M 10-Q · filed 2026-08-11 | $4.67M derived: sum of 3 quarters · filed 2026-08-11 | $5.40M derived: sum of 4 quarters · filed 2026-08-11 | ||
| 2025-03-31 | -$1.51M 10-Q · filed 2026-05-07 | $1.48M derived: sum of 2 quarters · filed 2026-05-07 | $2.21M derived: sum of 3 quarters · filed 2026-05-07 | $3.35M derived: sum of 4 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $2.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.72M derived: sum of 2 quarters · filed 2026-03-23 | $4.86M derived: sum of 3 quarters · filed 2026-03-23 | $1.47M 10-K · filed 2026-03-23 | ||
| 2024-09-30 | $733.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.87M derived: sum of 2 quarters · filed 2025-11-12 | -$1.52M 10-Q · filed 2025-11-12 | -$1.96M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$2.26M 10-Q · filed 2025-08-13 | -$2.69M derived: sum of 3 quarters · filed 2025-08-13 | -$2.82M derived: sum of 4 quarters · filed 2025-08-13 | ||
| 2024-03-31 | -$3.40M 10-Q · filed 2025-05-12 | -$3.83M derived: sum of 2 quarters · filed 2025-05-12 | -$3.96M derived: sum of 3 quarters · filed 2025-05-12 | -$6.15M derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2023-12-31 | -$438.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | -$561.00K derived: sum of 2 quarters · filed 2025-03-07 | -$2.76M derived: sum of 3 quarters · filed 2025-03-07 | -$7.09M 10-K · filed 2025-03-07 | ||
| 2023-09-30 | -$123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$2.32M derived: sum of 2 quarters · filed 2024-11-14 | -$6.66M 10-Q · filed 2024-11-14 | -$2.28M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$6.53M 10-Q · filed 2024-08-08 | -$2.15M derived: sum of 3 quarters · filed 2024-08-08 | -$9.48M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | -$4.34M 10-Q · filed 2024-05-15 | $42.00K derived: sum of 2 quarters · filed 2024-05-15 | -$7.29M derived: sum of 3 quarters · filed 2024-05-15 | -$8.08M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$2.95M derived: sum of 2 quarters · filed 2024-03-01 | -$3.74M derived: sum of 3 quarters · filed 2024-03-01 | -$14.09M 10-K · filed 2024-03-01 | ||
| 2022-09-30 | -$7.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$8.12M derived: sum of 2 quarters · filed 2023-11-09 | -$18.46M 10-Q · filed 2023-11-09 | -$19.12M derived: sum of 4 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$791.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$11.13M 10-Q · filed 2023-08-09 | -$11.79M derived: sum of 3 quarters · filed 2023-08-09 | -$15.23M derived: sum of 4 quarters · filed 2023-08-09 | ||
| 2022-03-31 | -$10.34M 10-Q · filed 2023-05-10 | -$11.00M derived: sum of 2 quarters · filed 2023-05-10 | -$14.44M derived: sum of 3 quarters · filed 2023-05-10 | -$30.27M derived: sum of 4 quarters · filed 2023-05-10 | ||
| 2021-12-31 | -$652.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | -$4.10M derived: sum of 2 quarters · filed 2023-03-01 | -$19.93M derived: sum of 3 quarters · filed 2023-03-01 | -$37.23M 10-K · filed 2023-03-01 | ||
| 2021-09-30 | -$3.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$19.27M derived: sum of 2 quarters · filed 2022-11-09 | -$36.57M 10-Q · filed 2022-11-09 | -$30.41M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-06-30 | -$15.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$33.13M 10-Q · filed 2022-08-08 | -$26.96M derived: sum of 3 quarters · filed 2023-03-01 | -$21.39M derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2021-03-31 | -$17.30M 10-Q · filed 2022-05-06 | -$11.14M derived: sum of 2 quarters · filed 2023-03-01 | -$5.56M derived: sum of 3 quarters · filed 2023-03-01 | -$767.00K derived: sum of 4 quarters · filed 2023-03-01 | ||
| 2020-12-31 | $6.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $11.74M derived: sum of 2 quarters · filed 2023-03-01 | $16.53M derived: sum of 3 quarters · filed 2023-03-01 | $5.98M 10-K · filed 2023-03-01 | ||
| 2020-09-30 | $5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $10.37M derived: sum of 2 quarters · filed 2021-11-08 | -$178.00K 10-Q · filed 2021-11-08 | $20.29M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-06-30 | $4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$5.75M 10-Q · filed 2021-08-05 | $14.72M derived: sum of 3 quarters · filed 2022-02-28 | $20.45M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2020-03-31 | -$10.55M 10-Q · filed 2021-05-06 | $9.92M derived: sum of 2 quarters · filed 2022-02-28 | $15.66M derived: sum of 3 quarters · filed 2022-02-28 | $2.78M derived: sum of 4 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $20.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $26.21M derived: sum of 2 quarters · filed 2022-02-28 | $13.33M derived: sum of 3 quarters · filed 2022-02-28 | $10.63M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | -$7.14M derived: sum of 2 quarters · filed 2020-11-09 | -$9.85M 10-Q · filed 2020-11-09 | -$7.88M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | -$12.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$15.58M 10-Q · filed 2020-08-10 | -$13.61M derived: sum of 3 quarters · filed 2021-02-26 | -$8.89M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | -$2.70M 10-Q · filed 2020-05-08 | -$7.28M 10-Q · filed 2019-05-10 | -$736.00K derived: sum of 2 quarters · filed 2021-02-26 | $3.99M derived: sum of 3 quarters · filed 2021-02-26 | -$9.98M derived: sum of 4 quarters · filed 2021-02-26 | |
| 2018-12-31 | $1.97M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $6.69M derived: sum of 2 quarters · filed 2021-02-26 | -$7.28M derived: sum of 3 quarters · filed 2021-02-26 | -$12.36M 10-K · filed 2021-02-26 | -$10.52M 10-K · filed 2019-02-28 | |
| 2018-09-30 | $4.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | -$9.25M derived: sum of 2 quarters · filed 2019-11-08 | -$14.32M 10-Q · filed 2019-11-08 | -$1.47M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-06-30 | -$13.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$19.05M 10-Q · filed 2019-08-05 | -$6.19M derived: sum of 3 quarters · filed 2020-02-27 | -$13.62M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2018-03-31 | -$5.08M 10-Q · filed 2019-05-10 | $7.78M derived: sum of 2 quarters · filed 2020-02-27 | $351.00K derived: sum of 3 quarters · filed 2020-02-27 | $6.47M derived: sum of 4 quarters · filed 2020-02-27 | ||
| 2017-12-31 | $12.86M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $5.43M derived: sum of 2 quarters · filed 2020-02-27 | $11.55M derived: sum of 3 quarters · filed 2020-02-27 | $8.33M 10-K · filed 2020-02-27 | $8.35M 10-K · filed 2018-02-28 | |
| 2017-09-30 | -$7.43M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$1.31M derived: sum of 2 quarters · filed 2018-11-08 | -$4.52M 10-Q · filed 2018-11-08 | $4.48M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-06-30 | $6.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $2.90M 10-Q · filed 2018-08-02 | $11.91M derived: sum of 3 quarters · filed 2019-02-28 | $14.37M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2017-03-31 | -$3.21M 10-Q · filed 2018-05-09 | $5.79M derived: sum of 2 quarters · filed 2019-02-28 | $8.25M derived: sum of 3 quarters · filed 2019-02-28 | $8.26M derived: sum of 4 quarters · filed 2019-02-28 | ||
| 2016-12-31 | $9.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $11.46M derived: sum of 2 quarters · filed 2019-02-28 | $11.47M derived: sum of 3 quarters · filed 2019-02-28 | $17.19M 10-K · filed 2019-02-28 | ||
| 2016-09-30 | $2.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $2.47M derived: sum of 2 quarters · filed 2017-11-08 | $8.19M 10-Q · filed 2017-11-08 | $17.08M derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2016-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.73M 10-Q · filed 2017-08-09 | $14.62M derived: sum of 3 quarters · filed 2018-02-28 | $17.90M derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2016-03-31 | $5.72M 10-Q · filed 2017-05-10 | $14.61M derived: sum of 2 quarters · filed 2018-02-28 | $17.89M derived: sum of 3 quarters · filed 2018-02-28 | $10.86M derived: sum of 4 quarters · filed 2018-02-28 | ||
| 2015-12-31 | $8.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $12.17M derived: sum of 2 quarters · filed 2018-02-28 | $5.14M derived: sum of 3 quarters · filed 2018-02-28 | -$1.04M 10-K · filed 2018-02-28 | ||
| 2015-09-30 | $3.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$3.74M derived: sum of 2 quarters · filed 2016-11-09 | -$9.93M 10-Q · filed 2016-11-09 | -$3.14M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-06-30 | -$7.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | -$13.21M 10-Q · filed 2016-08-09 | -$6.42M derived: sum of 3 quarters · filed 2017-03-01 | -$6.26M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-03-31 | -$6.18M 10-Q · filed 2016-05-10 | $600.00K derived: sum of 2 quarters · filed 2017-03-01 | $759.00K derived: sum of 3 quarters · filed 2017-03-01 | $933.00K derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2014-12-31 | $6.78M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $6.94M derived: sum of 2 quarters · filed 2017-03-01 | $7.12M derived: sum of 3 quarters · filed 2017-03-01 | $11.68M 10-K · filed 2017-03-01 | ||
| 2014-09-30 | $159.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $333.00K derived: sum of 2 quarters · filed 2015-11-12 | $4.90M 10-Q · filed 2015-11-12 | $5.96M derived: sum of 4 quarters · filed 2016-03-11 | ||
| 2014-06-30 | $174.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $4.74M 10-Q · filed 2015-08-13 | $5.80M derived: sum of 3 quarters · filed 2016-03-11 | $7.49M derived: sum of 4 quarters · filed 2016-03-11 | ||
| 2014-03-31 | $4.56M 10-Q · filed 2015-05-13 | $5.63M derived: sum of 2 quarters · filed 2016-03-11 | $7.31M derived: sum of 3 quarters · filed 2016-03-11 | $12.43M derived: sum of 4 quarters · filed 2016-03-11 | ||
| 2013-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11 | $2.75M derived: sum of 2 quarters · filed 2016-03-11 | $7.86M derived: sum of 3 quarters · filed 2016-03-11 | $4.17M 10-K · filed 2016-03-11 | ||
| 2013-09-30 | $1.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $6.80M derived: sum of 2 quarters · filed 2014-11-12 | $3.10M 10-Q · filed 2014-11-12 | |||
| 2013-06-30 | $5.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.42M 10-Q · filed 2014-08-14 | ||||
| 2013-03-31 | -$3.69M 10-Q · filed 2014-06-24 | |||||
| 2012-12-31 | -$1.70M 10-K · filed 2015-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |